Skip to main content
menu

Dr. Ruffolo operating at University of Rochester Medicine

Welcome to the Ruffolo Lab

Mission

The Ruffolo Lab aims to improve outcomes for patients with hepatopancreatobiliary (HPB) cancers — cancers of the pancreas, bile ducts and liver. We study tissue from patients and from mouse models to find new therapeutic targets, then turn those findings into early-phase clinical trials at the Wilmot Cancer Institute. Our work spans human tissue analysis, mouse modeling, data science and clinical trial development.

Immunofluorescence of normal mouse liver (top) and cholangiocarcinoma from the KPPC mouse model (bottom). Tumor-associated macrophages (F4/80, red) and granulocytic suppressor cells (Ly6G, red) crowd around cancer cells (CK7, green); nuclei in blue. Adapted from Ruffolo LI, et al. Gut. 2022;71(7):1386-1398, Figure 2B (CC BY-NC 4.0).Pancreatic Cancer, Bile Duct Cancer, and Liver Metastases

Pancreatic and bile duct cancers are among the deadliest solid tumors, and the liver is one of the most common places that cancers spread. Immunotherapy has transformed care for some cancers, but most patients with HPB cancers do not benefit. One reason is the tumor microenvironment: dense scar-like tissue (stroma) and suppressive immune cells, such as macrophages, that switch off the T cells meant to attack the cancer. Liver metastases add a further barrier, because the liver itself tends to dampen immune responses. Our lab asks how these cells work together to block anti-tumor immunity, and how to break that circuit.

From the Operating Room to the Lab and Back

As a surgical oncology lab, we start with patients. Tumor specimens removed during surgery, and paired biopsies collected before and during treatment on clinical trials, let us study the human disease directly with spatial transcriptomics and proteomics, RNA sequencing and single-cell assays. We test the most promising targets in genetically engineered mouse models of pancreatic cancer, combining immune-targeted drugs with standard chemotherapy. We also analyze large national and institutional clinical-genomic datasets to learn which patients respond to immunotherapy and why. Findings that hold up across these approaches become the basis for mechanism-driven clinical trials.

widget-6f31e519-68b

Luis I. Ruffolo, M.D.

Luis I. Ruffolo, M.D.
Principal Investigator

Publications

widget-f0e3bbda-df6

View All Publications

Affiliations

Contact Us

Ruffolo Lab
Medical Research Building Extension (MRBX)
Rooms 2-11001 and 2-11301
University of Rochester Medical Center
601 Elmwood Ave., Box Surgery
Rochester, NY 14642